Capsules. Basic physical and chemical properties: solid gelatin capsules with a pink body and a blue cap size “3”, which contain a white powder.
Composition and form of release
Selofen is produced in capsules containing 10 mg of the active substance. The main component is zaleplon.
The active ingredient of the drug – zaleplon refers to drugs of the pyrazolpyrimidine group, which differ in benzodiazepines, as well as other hypnotics. The active substance of the drug enters into action with the benzodiazepine GABA-a receptors, which are contained in the neural structures of the brain.
It is used in the treatment of sleep disorders associated with difficulty falling asleep. The use of the drug is justified only in the treatment of severe forms of sleep disorders.
Contraindicated in case of hypersensitivity to zaleplon, as well as severe forms of hepatic or renal failure, myasthenia gravis, severe forms of respiratory failure. The drug is not prescribed to children who are under 18 years of age and women during breastfeeding.
Application during pregnancy and lactation
The period of breastfeeding and pregnancy are important contraindications for the use of Selofen.
The drug is not prescribed to patients whose work activity requires increased concentration of attention and quick psychomotor reactions.
Method of administration and dosage
The drug can be prescribed only in the shortest possible courses, which do not exceed two weeks. The use of the drug is advisable for the treatment of problems with falling asleep. The capsules should be swallowed immediately before going to bed. Do not combine taking the drug with food intake, as this can cause a delayed development of its effect.
The recommended maximum dose of zaleplon is 10 mg. When prescribing Selofen, it is necessary to warn the patient that it is strictly forbidden to take the drug twice during one night.
Due to the fact that elderly people and patients suffering from liver dysfunction may be more sensitive to the effects of zaleplon, in order to prevent the occurrence of negative consequences from taking it, the recommended starting dose of the drug for this category of patients is 5 mg.
When the drug is prescribed to patients with severe renal impairment, no dosage adjustment is performed.
There is no information on acute overdose with zaleplon. However, it can be assumed that taking Selofen in high doses can cause depression of the central nervous system, increased drowsiness, decreased blood pressure, confusion, respiratory failure, coma, and in especially difficult cases, death.
At the same time taking the drug in a high dosage, the patient undergoes gastric lavage and provides activated carbon.
In severe cases, the introduction of the antidote zaleplon – flumazenil is indicated.
Anorexia, somnambulism, apathy, hallucinations, depression, amnesia, angioedema, confusion, ataxia, visual impairment, dyspeptic disorders.
Storage conditions and periods
Selofen must be stored in its original packaging in places that are out of the reach of children. The storage period for capsules is 2 years.